Horizon Discovery News and Activities

Horizon Discovery is owned by Revvity.

Revvity is one of the...

• Fortune 500 (#961);
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Revvity is a company listed under the stock ticker RVTY (US).

Revvity has a direct presence in 3 countries.

Revvity has 5 subsidiaries including BioLegend, Euroimmun and Horizon Discovery.

They are in:

• Biotechnology50%
• Healthcare17%
• Other33%

View the org chart displaying its 2 main executives

Most searched biographies at Horizon Discovery

• Kelly Grimsley, Head of Operations
• Pearce Alex, Business Development, Sales Executive

Popular executive movements at Revvity

• Anita Gonzales who was Controller, becomes Vice President, Chief Accounting Officer  (posted on October 28 2025).

Create your alert
to follow the executive moves at Horizon Discovery.

Revvity has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Horizon Discovery

• MDIC Partners with HD to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics
• iTreg Suppression Assay Service
• MDIC Partners with PKIHD to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics
• Medical Device Innovation Consortium Launches Initiative to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics
• Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics
• cDNA & ORF clones
• MGC cDNAs
• Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics
• PerkinElmer’s Horizon Discovery CHOSOURCE Platform Expanding To Include CHO-K1 ADCC+ Expression Cell Line for Development of Therapeutic Antibodies in Oncology, Infectious Disease and Autoimmune ConditionsMenu
• Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM BioMenu
• View more press releases Close

Social media about Horizon Discovery

• Horizon Discovery on Wikipedia, Google News & Yahoo Finance
• Horizon Discovery on LinkedIn, X (Twitter) & YouTube